Ojemda is the first FDA-approved targeted therapy for children 6 months and older with relapsed or treatment-resistant pediatric low-grade glioma (pLGG) caused by certain BRAF gene changes.
To Get Full Access :
To Get Full Access :
Ojemda is the first FDA-approved targeted therapy for children 6 months and older with relapsed or treatment-resistant pediatric low-grade glioma (pLGG) caused by certain BRAF gene changes.
Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets
For full access Sign-up / Sign-in using below Methods:
By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.
